Trial results

A Study of Weight Loss Intervention With Tirzepatide and Progestin Intrauterine Device to Treat Endometrial Hyperplasia and Grade 1 Endometrial Cancer

NCT07349641 on ClinicalTrials.gov · last registry update 2026-08-26

A small phase 2 — 55 participants, against a typical 114. Due to report 31 October 2029, alongside 5 other tracked readouts that quarter. Primary outcome, as filed: Weighted pathological complete response (pCR). Sponsors move these dates routinely; any movement since this site started watching is listed below. tirzepatide is approved in the US, but not for cancer — a registration here is not an approval, and most drugs tested in a new condition never get one for it. The registry entry has been edited 1 time since then.

Status

NOT_YET_RECRUITING

Phase

P2

Drug

tirzepatide

Zepbound, Mounjaro

Sponsor

National Cancer Institute (NCI)

Sponsor type

Nih

Enrollment

55

Started

2026-11-01

Primary completion

2029-10-31 estimated

Observed history

Every change this record has made since we started watching it. ClinicalTrials.gov shows only the current value. When a field is edited the previous one is overwritten and nothing is published to say so, so this history exists only because someone was recording it at the time.

Primary outcome

Weighted pathological complete response (pCR)

Conditions studied

Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia · FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma

Every field above is taken directly from the registry record. See all detected changes across the class, or the tirzepatide page for this molecule’s full trial and approval history.